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Cystatin C as an Early Biomarker of Nephropathy in Patients with 
Type 2 Diabetes
This study was done to evaluate clinical usefulness of cystatin C levels of serum and urine 
in predicting renal impairment in normoalbuminuric patients with type 2 diabetes and to 
evaluate the association between albuminuria and serum/urine cystatin C. Type 2 diabetic 
patients (n = 332) with normoalbuminuria (n = 210), microalbuminuria (n = 83) and 
macroalbuminuria (n = 42) were enrolled. Creatinine, urinary albumin levels, serum/urine 
cystatin C and estimated glomerular filtration rate (eGFR by MDRD [Modification of Diet in 
Renal Disease] and CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] 
equations) were determined. The cystatin C levels of serum and urine increased with 
increasing degree of albuminuria, reaching higher levels in macroalbuminuric patients (P < 
0.001). In multiple regression analysis, serum cystatin C was affected by C-reactive protein 
(CRP), sex, albumin-creatinine ratio (ACR) and eGFR. Urine cystatin C was affected by 
triglyceride, age, eGFR and ACR. In multivariate logistic analysis, cystatin C levels of serum 
and urine were identified as independent factors associated with eGFR < 60 mL/min/1.73 
m
2 estimated by MDRD equation in patients with normoalbuminuria. On the other hand, 
eGFR < 60 mL/min/1.73 m
2 estimated by CKD-EPI equation was independently associated 
with low level of high-density lipoprotein in normoalbuminuric patients. The cystatin C 
levels of serum and urine could be useful markers for renal dysfunction in type 2 diabetic 
patients with normoalbuminuria. 
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INTRODUCTION
The number of people with diabetes is increasing due to popu-
lation growth, aging, urbanization and the increasing prevalence 
of obesity and physical inactivity. According to the World Health 
Organization (WHO), the prevalence of diabetes for all age-groups 
worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030 
(1). Estimation of the prevalence of earlier stages of chronic kid-
ney disease (CKD) in the US population and ascertainment of 
trends over time is central to disease management and preven-
tion planning, particularly given the increased prevalence of 
obesity and diabetes (2). To prevent this increase, screening for 
CKD and early intervention are necessary. In diabetic patients, 
the early detection of diabetic nephropathy has focused on the 
measurement of urinary albumin excretion rate. The elevated 
urinary albumin excretion rate within microalbuminuric level 
(30-299 mg/24 hr or a spot urine albumin-to-creatinine ratio of 
30-299 mg/g) allows the detection of patients with an increased 
risk for the development of overt diabetic nephropathy with per-
sistent macroalbuminuria. Moreover, impaired renal function 
may be present even in patients with normal urinary albumin 
excretion rate (3). Gold standard procedures for glomerular fil-
tration rate (GFR) measurement, based on the clearance of 
51Cr-
EDTA or iohexol, are impractical in clinical settings and for larg-
er research studies.
  Cystatin C, a cysteine protease inhibitor, is freely filtered by 
the renal glomeruli, metabolized by the proximal tubule and 
identified as a promising marker of renal failure (4). Cystatin C 
is produced at a constant rate by nucleated cells and released 
into bloodstream with a half-life of 2 hr. Its concentration is al-
most totally dependent on GFR. Other studies have demon-
strated that serum cystatin C is an early renal marker in diabetic 
patients (5-7), but not all studies have done so (8). 
  Thus, we explored the possibility of the cystatin C levels of se-
rum and urine as markers of early renal impairment in normo-
albuminuric patients with diabetes. We also evaluated the rela-
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335 patients with type 2 diabetes who visited our hospital be-
tween January 2008 and October 2009. We recorded confiden-
tial information of name, age, gender, race, height, weight and 
history of renin-angiotesin system inhibitors or antihyperten-
sive medication. Because thyroid function could affect the levels 
of cystatin C (9), we excluded the patients with thyroid disease, 
or taking the medication due to thyroid disease in 6 months. We 
also excluded patients with uncontrolled hypertension making 
an effect on albuminuria.
  The cystatin C levels of serum and urine were measured by 
the latex agglutination test (Modular P800, Roche, Diagnostics, 
Mannhein, Germany). The eGFR level was calculated using the 
Modification of Diet in Renal Disease (MDRD) formula: MDRD 
= 186 × (serum creatinine [mg/dL])
-1.154 × age
-0.203 (10). A correc-
tion factor of 0.742 was used for women. The eGFRcys level was 
calculated by the Chronic Kidney Disease Epidemiology (CKD-
EPI) equation: eGFR = 127.7 × (cystatin C in mg/L)
-1.17 × (age in 
years)
-0.13 × (0.91 if female) (11). Patients were divided into 3 groups 
according to their urinary albumin concentration: those with 
normoalbuminuria (n = 210), those with microalbuminuria (n = 
83) and those with macroalbuminuria (n = 42). Moreover, nor-
moalbuminuric patients were subdivided according to eGFR 
calculated by the MDRD formula: those with ≥ 60 mL/min/1.73 
m
2 (n = 181) and those with GFR < 60 mL/min/1.73 m
2 (n = 29).
Statistical analysis 
In statistical analysis, SPSS for Windows (version 13.0) were used. 
Data are presented as mean ± SD for normally distributed val-
ues. Differences between the groups were analyzed by ANOVA, 
followed by the Bonferroni’s test for normally distributed values 
and by the Kruskal-Wallis test, as well as the Dunn’s test for non-
parametric values. Pearson’s correlation coefficient was em-
ployed to test the correlations between different variables. Be-
fore testing correlations, all non-normally distributed values 
were log-transformed to better approximate normal distribu-
tions. After correlation analysis, stepwise multiple linear regres-
sion was performed with the variables to find the factor that ef-
fects the cystatin C levels of serum and urine. Receiver operat-
ing characteristics (ROC) analysis was employed to calculate the 
area under the curve (AUC) for the cystatin C levels of serum 
and urine to find the best cutoff values for identifying renal im-
pairment in diabetic patients. Logistic regression was performed 
to find the predicting factors for renal impairment in normoal-
buminuric patients. All results were considered significant if P 
< 0.05.
Ethics statement
The study was approved by the institutional review board of the 
Pusan University Hospital, Busan, Korea (IRB review exemption 
No. 0740-1289).
Table 1. Characteristics of metabolic and laboratory parameters in patients with type 2 diabetes 
Parameters Normo-albuminuria Micro-albuminuria Macro-albuminuria P value
Sex (male/female)     92/118   46/37   22/20 0.163
Age (yr)   58.0 ± 12.0   59.2 ± 11.1 61.8 ± 8.8 0.135
ACR (mg/g) 11.6 ± 6.8   89.8 ± 64.9   1,403.8 ± 1,001.5 < 0.001
BMI (kg/m
2) 24.6 ± 4.1 24.5 ± 3.1 23.8 ± 3.3 0.391
SBP (mmHg) 121.9 ± 12.3 124.2 ± 15.6 129.8 ± 22.4 0.006
DBP (mmHg) 74.3 ± 8.9   74.5 ± 11.4   74.9 ± 12.4 0.936
FBS (mg/dL) 155.3 ± 59.1 180.0 ± 99.0 190.9 ± 83.1 0.003
HbA1C (%)   7.3 ± 1.5   7.8 ± 1.9   7.9 ± 1.6 0.015
RAS inhibitors, n (% yes)   95 (45) 59 (71)    38 (90) < 0.001
Lipid lowering agent, n (% yes) 119 (57) 50 (60) 9/33 (79) 0.016
anti-HT Tx, n (% yes)   62 (30) 44 (53)    37 (88) < 0.001
eGFR calculated by the MDRD equation (mL/min/1.73 m
2)   84.6 ± 23.3   76.0 ± 27.8   44.9 ± 26.6 < 0.001
eGFR calculated by the CKD-EPI equation (mL/min/1.73 m
2)   86.2 ± 22.0   77.2 ± 27.2   43.6 ± 24.4 < 0.001
BUN (mg/dL)   17.2 ± 13.7 19.2 ± 8.9   34.5 ± 22.5 < 0.001
Serum Cr (mg/dL)   0.9 ± 0.2   1.1 ± 0.4   2.3 ± 1.9 < 0.001
Total cholesterol (mg/dL) 172.7 ± 47.4 172.6 ± 43.4 175.2 ± 44.3 0.945
LDL (mg/dL)   95.9 ± 30.5   93.0 ± 31.9   93.1 ± 34.1 0.713
HDL (mg/dL)   46.0 ± 12.6   43.4 ± 11.4   43.1 ± 13.7 0.147
TG (mg/dL) 150.4 ± 88.3   182.9 ± 118.4   187.5 ± 119.2 0.012
CRP (mg/dL)   0.16 ± 0.36   0.19 ± 0.44   0.35 ± 1.22 0.128
Serum cystatin C (mg/L)   0.91 ± 0.26   1.05 ± 0.38   2.04 ± 1.19 < 0.001
Urine cystatin C (mg/L)   0.06 ± 0.06   0.32 ± 1.14  1.17 ±2.73 < 0.001
Urine cystatin/Cr × 10
-1   1.00 ± 1.49     9.06 ± 40.19     16.84 ± 104.43 < 0.001
FeCyst (%)   0.09 ± 0.13   1.10 ± 6.27   5.26 ± 12.8 <0.001
Data are expressed as mean ± SD for continuous variables and frequency (%) for categorical variables. P values by ANOVA and the chi-square test. ACR, albumin creatinine 
ratio; anti-HT Tx, anti-hypertension treatment; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatitine; CRP, C-reactive protein; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBS, fasting blood sugar; FeCyst, fractional excretion of cystatin C; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; MDRD, Modification of Diet in Renal Disease; RAS, renin-angiotesin system; SBP, systolic blood pressure; TG, Triglyceride.Jeon YK, et al.  •  Cystatin C in Type 2 Diabetes
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RESULTS
Patient characteristics
Patients were categorized into 3 groups depending on their uri-
nary albumin excretion evaluated using the urine albumin/cre-
atinine ratio (ACR) (mg/g creatinine): the macroalbuminuric, 
microalbuminuric and normoalbuminuric groups. The base-
line characteristics of the subjects are shown in Table 1. There 
were no significant differences in age and sex between the 3 
groups. However, eGFR was significantly lower in the macroal-
buminuric group (44.9 ± 26.6) than in the microalbuminuric 
(76.0 ± 27.8) and normoalbuminuric groups (84.6 ± 23.3) (P < 
0.001). A high ACR was associated with antihypertensive 
agents, renin-angiotensin system (RAS) inhibitors, lipid lower-
ing agents, high HbA1C/glucose, low eGFR and high triglycer-
ides (Table 1).
Differences in the cystatin C levels of serum and urine 
according to albuminuria
The levels of cystatin C in serum showed stepwise increase with 
albuminuric levels (P < 0.001, P = 0.013, respectively) (Table 1, 
Fig. 1). Serum cystatin C was significantly different according to 
their albuminuria (normoalbuminuria vs microalbumiuria, P  
< 0.01; microalbumiuria vs macroalbuminuria, P < 0.001; nor-
moalbuminuria vs macroalbuminuria, P < 0.001) (Table 1, Fig. 
1A). The level of urine cystatin C also showed stepwise increase 
with albuminuric level (normoalbuminuria vs microalbumi-
uria, P < 0.05; microalbumiuria vs macroalbuminuria, P < 0.001; 
normoalbuminuria vs macroalbuminuria, P < 0.001) (Table 1, 
Fig. 1B).
Parameters related to the cystatin C levels of serum and 
urine in diabetic patients
The correlations between the log-transformed cystatin C levels 
of serum and urine and the albumin creatinine ratio were ana-
lyzed in all diabetic patients. The serum level of cystatin C was 
found to directly correlate with albuminuria (r = 0.555, P < 0.001). 
The urine level of cystatin C also positively correlated with albu-
minuria (r = 0.500, P < 0.001). In Pearson’s correlation analysis, 
the serum level of cystatin C was related to age, ACR, creatinine, 
eGFR, C-reactive protein (CRP), high-density lipoprotein and 
systolic blood pressure; and the urine level of cystatin C was re-
lated to ACR, HbA1C, creatinine, GFR, CRP and glucose. We per-
formed a stepwise multiple regression analysis with these fac-
tors. The serum level of cystatin C was related to CRP, ACR and 
GFR, and the urine level of cystatin C was related to triglyceride, 
age, eGFR and ACR. 
Table 2. Baseline characteristics of 210 diabetic patients with normoalbuminuria 
defined by using estimated eGFR (mL/min/1.73 m
2) calculated by the MDRD equation 
Parameters eGFR ≥ 60 eGFR < 60 P value
Sex (male/female) 80/101 12/17 0.776
Age (yr)   56.5 ± 11.9 67.1 ± 7.8 < 0.001
ACR (mg/g) 11.4 ± 6.5 13.1 ± 8.3 0.219
BMI (kg/m
2) 24.8 ± 4.1 23.8 ± 3.8 0.213
SBP (mmHg) 121.5 ± 12.2 124.1 ± 13.0 0.303
DBP (mmHg) 74.2 ± 8.8   74.5 ± 10.0 0.869
FBS (mg/dL) 157.3 ± 59.4 143.4 ± 57.1 0.242
HbA1C (%)   7.4 ± 1.5   6.9 ± 1.0 0.068
RAS inhibitors, n (% yes)   79 (44) 16 (55) 0.247
Lipid lowering agent, n (% yes) 104 (57) 15 (52) 0.563
anti-HT Tx, n (% yes)   49 (27) 12 (41) 0.123
eGFR calculated by the MDRD  
   equation (mL/min/1.73 m
2)
  89.7 ± 20.6 52.3 ± 8.5 < 0.001
eGFR calculated by the CKD-EPI  
   equation (mL/min/1.73 m
2)
  90.0 ± 20.0  64.7 ±20.4 < 0.001
BUN (mg/dL)   16.7 ± 14.3 20.4 ± 8.5 0.173
serum Cr (mg/dL)   0.84 ± 0.16   1.25 ± 0.27 < 0.001
T.chol (mg/dL) 173.4 ± 49.3 168.5 ± 34.2 0.513
LDL (mg/dL)   96.1 ± 31.0   94.9 ± 27.4 0.846
HDL (mg/dL)   46.9 ± 12.4   40.3 ± 12.2 0.008
TG (mg/dL) 147.7 ± 85.4   167.1 ± 105.1 0.272
CRP (mg/dL)   0.16 ± 0.38   0.11 ± 0.11 0.471
Serum cystatin-C (mg/L)  0.86 ±0.18   1.21 ± 0.42 < 0.001
Urine cystatin-C (mg/L)   0.055 ± 0.445   0.108 ± 0.108 0.013
Urine cystatin/Cr × 10
-1  0.86 ±1.06 1  .93 ± 2.87 0.056
FeCyst (%)   0.075 ± 0.092   0.178 ± 0.250 0.036
Data are expressed as mean ± SD for continuous variables and frequency (%) for 
categorical variables. P values were obtained by the independent sample table t test. 
Abbreviations as in Table 1.
Fig. 1. Cystatin C in patient groups with normoalbuminuria (NA), microalbuminuria (MA) or macroalbuminuria (diabetic nephropathy, DN). (A) Serum cystatin C. *P < 0.01 NA vs 
MA; 
†P < 0.001 MA vs DN; 
‡P < 0.001 NA vs DN. (B) Urine cystatin C. *P < 0.05 NA vs MA; 
†P < 0.01 MA vs DN; 
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Differences in the cystatin C levels of serum and urine 
according to eGFR in the normoalbuminuric group
Table 2 presents the clinical characteristics of 210 patients with 
normoalbuminuria according to their eGFR. The patients with 
eGFR < 60 mL/min/1.73 m
2 (n = 29, 14%) by the MDRD equa-
tion were older, had lower high density lipoprotein levels (40.3 ± 
12.2 vs 46.9 ± 12.4 mg/dL, P = 0.008), had higher cystatin C levels 
of serum (1.21 ± 0.42 vs 0.86 ± 0.18 mg/L, P < 0.001) and urine 
(0.11 ± 0.11 vs 0.06 ± 0.45 mg/L, P = 0.013) than those with eGFR 
≥ 60 mL/min/1.73 m
2. However, there were no significant dif-
ferences in ACR.
ROC Analysis of cystatin C levels of serum and urine
ROC analyses were performed to define the diagnostic profile 
of the serum and urine levels of cystatin C for detecting eGFR < 
60 mL/min/1.73 m
2 among subjects with type 2 diabetes. The 
serum level of cystatin C showed an AUC of 0.906 (95% CI, 0.865-
0.947) with a cutoff value of 1.06 (sensitivity, 81.0%; specificity, 
87.1%). Also, the urine level of cystatin C supported the diag-
nostic profile, showing an AUC of 0.807 (95% CI, 0.741-0.873) 
with a cutoff value of 0.1 (sensitivity, 70.9%; specificity, 86.3%) 
(Fig. 2).
Predictive factors for eGFR < 60 mL/min/1.73 m
2 in 
normoalbuminuric patients with diabetes
We performed logistic regression analysis with ACR, CRP, glu-
cose, low-density lipoprotein, triglyceride, high-density lipopro-
tein, and the cystatin C levels of serum and urine. In normoal-
Table 3. Independent factors associated with eGFR < 60 mL/min/1.73 m
2 calculated 
by the MDRD equation and EPI-equation in normoalbuminuric patients 
Variables Odds ratio 95% Confidence interval P value
MDRD equation
   Serum cystatin C


















CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; HDL, high-density 
lipoprotein; MDRD, Modification of Diet in Renal Disease. 
Fig. 2. ROC curves of cystatin C in serum and urine in reference to eGFR < 60 mL/
min/1.73 m
2 calculated by the MDRD equation. The AUC for was 0.906 (95% CI, 
0.865-0.947) for serum cystatin C and 0.807 (95% CI, 0.741-0.873), for urine cystatin 
C. For serum cystatin C, the cutoff value for the identification of eGFR < 60 mL/min/ 
1.73 m
2 conducted by the MDRD equation was found to be 1.06 mg/L with a sensitivity 
of 81.0% and a specificity of 87.1%, whereas for urine cystatin C, it was 0.1 mg/L 
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buminuric patients, eGFR < 60 mL/min/1.73 m
2 by the MDRD 
equation was related to normal cystatin C levels of serum and 
urine by the cutoff value that was calculated from the ROC curve. 
When we used the EPI-equation, the factors which we put in 
logistic regression were ACR, CRP, glucose, low-density lipopro-
tein, triglyceride, high-density lipoprotein and the urine level of 
cystatin C. eGFR < 60 mL/min/1.73 m
2 was independently re-
lated to the lower level of high-density lipoprotein (Table 3). 
 
DISCUSSION
In this study, we aimed at evaluating the cystatin C levels of se-
rum and urine in a small cohort of patients with type 2 diabetes 
by categorizing them into 3 groups depending on their different 
degrees of kidney damage (normalbuminuria, microalbumin-
uria and diabetic nephropathy). In normoalbuminuric patients, 
the cystatin C levels of serum and urine were significantly in-
creased in patients with GFR ≤ 60 mL/min/1.73 m
2 than those 
with GFR > 60 mL/min/1.73 m
2. It was thought that this incre-
ment was probably due to the tubular phase before glomerular 
manifestation. This suggests that the cystatin C levels of serum 
and urine are related to subclinical tubular impairment and can 
be an earlier measurable markers of renal involvement before 
onset of albuminuria. In these patients, the cystatin C levels of 
serum and urine were independent factors to predict eGFR < 60 
mL/min/1.73 m
2 estimated by the MDRD equation. This find-
ing indicated that the cystatin C could be an index reflecting re-
nal tubular epithelial cells. With the EPI equation, the decreased 
level of high-density lipoprotein was the only independent fac-
tor to predict eGFR < 60 mL/min/1.73 m
2. This result is consis-
tent with those of previous studies demonstrating that lipid me-
tabolism may participate in the development of glomerular and 
tubular alterations, leading to nephron destruction. Our results 
suggest that dyslipidemia can be a risk factor for kidney damage 
in normoalubminuric diabetic patients. Further studies are need-
ed to confirm these results.
  Our study showed that serum cystatin C was associated with 
CRP, ACR and eGFR, whereas urine cystatin C was associated 
with TG, age, eGFR and ACR in the stepwise multiple regression 
analysis. A recent study has suggested the relationship between 
cystatin C and factors such as old age, male, overweight, CRP (12), Jeon YK, et al.  •  Cystatin C in Type 2 Diabetes
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and inflammation (13). Our results are consistent with those 
studies. 
  The routine classical evaluation of diabetic nephropathy in-
cludes appearance of microalbuminuria, decreased creatinine 
clearance and increased serum creatinine (14). But, it has been 
reported that a decline in the renal function of patients with di-
abetes was not always accompanied by an increased ACR (15, 
16). About 20%-30% of patients with type 2 diabetes, accompa-
nied by renal insufficiency, showed normoalbuminuria (15-20). 
To overcome these limitations, many clinicians additionally used 
creatinine in evaluating such patients. However, serum creati-
nine also depends on creatinine production, extrarenal elimi-
nation and tubular handling (21). Moreover, tubular involve-
ment may precede glomerular involvement because several tu-
bular proteins and enzymes are detectable even before the ap-
pearance of microalbuminuria and a rise in serum creatinine 
(22, 23). Therefore, other biomarkers for estimation of renal func-
tion have been searched for and one of them was cystatin C (24). 
Our study results confirmed that cystain C could be one of the 
additional tubular factors which represent kidney state of dia-
betic patients. 
  This study has some limitations. First, owing to the retrospec-
tive cross sectional design, it was difficult to clarify the causal 
relationship between the risk factors and the natural course of 
normoalbuminuric renal insufficiency. Moreover, the patients 
with normoalbuinuria and eGFR < 60 mL/min/1.73 m
2 might 
need more evaluation such as kidney biopsy to diagnose dia-
betic nephropathy. Second, eGFR, estimated by the MDRD or 
EPI-equation, did not appear to reflect actual kidney function. 
So, we could not conclude that which factor is more accurate or 
useful. Third, the subjected patients were not asked to discon-
tinue their medications, such as antihypertensive medications. 
Therefore, albuminuria might be underestimated in these pa-
tients. Nevertheless, this study has some strength. We evaluated 
the levels of cystatin C in both serum and urine at the same time. 
In addition, this study demonstrated clearly that the cystatin C 
levels of serum and urine were increased along with the level of 
albuminuria in diabetic patients. 
  In conclusion, the results of this study suggest that cystatin C 
measurement in urine and serum is a useful, practical, non-inva-
sive tool for the evaluation of renal involvement in the course of 
diabetes, especially in normoalbuminuric patients. Further in-
vestigations with a larger sample size and a prospective design 
are required to confirm the potential application of cystatin C 
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In type 2 diabetic patients, the early detection of diabetic nephropathy has focused on the measurement of urinary albumin 
excretion rate, but impaired renal function may be present even in patients with normoalbuminuria. Cystatin C, a cysteine 
protease inhibitor, is freely filtered by the renal glomeruli, metabolized by the proximal tubule and identified as a promising marker 
of renal failure. In our study, the cystatin C levels of serum and urine increased with increasing degree of albuminuria, reaching 
higher levels in macroalbuminuric patients. Especially, in normoalbuminuric patients, serum and urine cystatin C were identified 
as independent factors associated with eGFR < 60 mL/min/1.73 m
2 estimated by MDRD equation. The cystatin C levels of serum 
and urine could be useful markers for renal dysfunction in type 2 diabetic patients with normoalbuminuria. 